JP2017500306A - 脳障害を治療する、またはそれに関連した生物マーカーを同定する方法 - Google Patents

脳障害を治療する、またはそれに関連した生物マーカーを同定する方法 Download PDF

Info

Publication number
JP2017500306A
JP2017500306A JP2016538538A JP2016538538A JP2017500306A JP 2017500306 A JP2017500306 A JP 2017500306A JP 2016538538 A JP2016538538 A JP 2016538538A JP 2016538538 A JP2016538538 A JP 2016538538A JP 2017500306 A JP2017500306 A JP 2017500306A
Authority
JP
Japan
Prior art keywords
disorder
patient
brain
glyx
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016538538A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017500306A5 (https=
Inventor
ジョーゼフ モスカル
ジョーゼフ モスカル
Original Assignee
ノースウェスタン ユニバーシティ
ノースウェスタン ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノースウェスタン ユニバーシティ, ノースウェスタン ユニバーシティ filed Critical ノースウェスタン ユニバーシティ
Publication of JP2017500306A publication Critical patent/JP2017500306A/ja
Publication of JP2017500306A5 publication Critical patent/JP2017500306A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
JP2016538538A 2013-12-13 2014-12-15 脳障害を治療する、またはそれに関連した生物マーカーを同定する方法 Pending JP2017500306A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361915835P 2013-12-13 2013-12-13
US61/915,835 2013-12-13
PCT/US2014/070340 WO2015089503A2 (en) 2013-12-13 2014-12-15 Methods of treating brain disorders or identifying biomarkers related thereto

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019153406A Division JP2020007333A (ja) 2013-12-13 2019-08-26 脳障害を治療する、またはそれに関連した生物マーカーを同定する方法

Publications (2)

Publication Number Publication Date
JP2017500306A true JP2017500306A (ja) 2017-01-05
JP2017500306A5 JP2017500306A5 (https=) 2018-02-01

Family

ID=53371976

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016538538A Pending JP2017500306A (ja) 2013-12-13 2014-12-15 脳障害を治療する、またはそれに関連した生物マーカーを同定する方法
JP2019153406A Pending JP2020007333A (ja) 2013-12-13 2019-08-26 脳障害を治療する、またはそれに関連した生物マーカーを同定する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019153406A Pending JP2020007333A (ja) 2013-12-13 2019-08-26 脳障害を治療する、またはそれに関連した生物マーカーを同定する方法

Country Status (9)

Country Link
US (1) US20160345855A1 (https=)
EP (2) EP3079579A4 (https=)
JP (2) JP2017500306A (https=)
CN (2) CN106102762A (https=)
AU (2) AU2014361822A1 (https=)
CA (1) CA2933372A1 (https=)
IL (2) IL246148A0 (https=)
MX (1) MX2016007716A (https=)
WO (1) WO2015089503A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018530593A (ja) * 2015-10-16 2018-10-18 ノースウェスタン ユニバーシティ 統合失調症、双極性障害、認知障害及び大うつ病性障害の治療のための非定型的抗精神病薬ならびにｎｍｄａ調節剤の医薬品の組み合わせ
US20220024976A1 (en) * 2019-01-11 2022-01-27 Naurex Inc. Salt and crystalline forms of rapastinel
CN110123342B (zh) * 2019-04-17 2021-06-08 西北大学 一种基于脑电波的网瘾检测方法及系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539991A (ja) * 2006-06-15 2009-11-19 マース インコーポレーテッド 認知機能改善のための方法及び組成物
WO2013106084A1 (en) * 2012-01-09 2013-07-18 Takeda Pharmaceutical Company Limited Methods and drug products for treating alzheimer's disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20050273017A1 (en) * 2004-03-26 2005-12-08 Evian Gordon Collective brain measurement system and method
US20090253982A1 (en) * 2006-04-03 2009-10-08 Jiongjiong Wang Assessing subject's reactivity to psychological stress using fmri
US8951968B2 (en) * 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
PL2485751T3 (pl) * 2009-10-05 2014-10-31 Univ Northwestern GLYX-13 do stosowania w sposobie leczenia depresji opornej na leczenie
US20140107037A1 (en) * 2011-04-27 2014-04-17 Northwestern University Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539991A (ja) * 2006-06-15 2009-11-19 マース インコーポレーテッド 認知機能改善のための方法及び組成物
WO2013106084A1 (en) * 2012-01-09 2013-07-18 Takeda Pharmaceutical Company Limited Methods and drug products for treating alzheimer's disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"View of NCT01844726 on 2013_05_23", CLINICALTRIALS.GOV ARCHIVE, JPN6018034401, 23 May 2013 (2013-05-23), ISSN: 0004022908 *
EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 23, no. 2, JPN6018034402, 20 November 2013 (2013-11-20), pages 243 - 254, ISSN: 0004022909 *

Also Published As

Publication number Publication date
EP3721799A1 (en) 2020-10-14
WO2015089503A3 (en) 2015-10-01
JP2020007333A (ja) 2020-01-16
AU2014361822A1 (en) 2016-07-28
EP3079579A2 (en) 2016-10-19
CN106102762A (zh) 2016-11-09
AU2019264583A1 (en) 2019-12-05
IL246148A0 (en) 2016-07-31
CA2933372A1 (en) 2015-06-18
US20160345855A1 (en) 2016-12-01
MX2016007716A (es) 2017-03-31
WO2015089503A2 (en) 2015-06-18
IL276431A (en) 2020-09-30
CN111920412A (zh) 2020-11-13
EP3079579A4 (en) 2017-07-19

Similar Documents

Publication Publication Date Title
RU2499598C2 (ru) Способы лечения нарушений с применением селективного антагониста nr2b-подтипа nmda рецепторов
JP7642735B2 (ja) アルツハイマー病を治療するための抗ａベータプロトフィブリル抗体及びベータ－セクレターゼｂａｃｅ１阻害剤を含む組成物
EP4304591A1 (en) Pharmaceutical composition for the treatment of alzheimer's disease or dementia
KR20190013820A (ko) 일주기 리듬 수면 장애를 치료하는 방법
JP2020007333A (ja) 脳障害を治療する、またはそれに関連した生物マーカーを同定する方法
JP2009521403A (ja) Ｍｒｉによる神経発生の相関の画像法
Fu et al. Inhibition of TREM-1 ameliorates Lipopolysaccharide-induced depressive-like behaviors by alleviating neuroinflammation in the PFC via PI3K/Akt signaling pathway
WO2020165802A1 (en) Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors
WO2020118282A1 (en) Methods, compositions and kits for treating multiple sclerosis and other disorders
HK40040750A (en) Methods of treating brain disorders or identifying biomarkers related thereto
AU4301699A (en) Use of 4-piperidinemethanol derivatives in treatment of neurodevelopmental disorders
KR20230167032A (ko) 인지 장애의 치료를 위한 화합물
WO2022040606A1 (en) Compositions and methods to reduce neuroinflammation
Raith Preclinical telemetric EEG recordings and behavioral measurements to investigate efficacy and tolerability in psychiatric drug discovery
Ladea et al. Brain derived neurotrophic factor levels and hippocampal volume in depressed patients treated with escitalopram
Toyohara et al. Roles of σ1 receptors in the mechanisms of action of CNS drugs
Lee et al. P. 6. a. 001 Augmentation therapy of aripiprazole with escitalopram in patients with co-occurrence of depression and alcohol dependence
WO2025054309A9 (en) Methods of identifying and treating patients having neurodegenerative disease based on plasma biomarker levels
Oh-Nishi et al. Reduction of dopmamine D2 receptor binding in medial prefrontal cortex in schizophrenia animal model with maternal immune activation
Yoshikawa et al. Analysis of strain-dependent prepulse inhibition points to a role for Shmt1 (SHMT1) in mice and in schizophrenia
Umino et al. Profiling of developmental changes in the gene expression following systemic administration of a schizophrenomimetic NMDA receptor antagonist phencyclidine in the rat neocortex
Wilson et al. A double‐blind dose‐determination study with flutroline: A new neuroleptic
Woods et al. Visual cortical plasticity and the risk for psychosis: An interim analysis of the North American Prodrome Longitudinal Study
Tsukahara et al. PT547. 17alfa-estradiol prevents gamma-aminobutyric signaling dysfunction induced by repeated stress in the hippocampus associated with behavioral abnormalities via G-protein-coupled estrogen receptor in ovariectomized mice
JP2021512857A (ja) Ｎｍｄａ受容体アゴニストの投与方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180903

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190425